Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 9/20 | 0.37 |
| ▸ | XPO1 | O14980 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10087558 | 0.93 | IDO1 (0.44) | IDO1KMT2APAX8HTR2AHTR2C | |
| SCHEMBL18719954 | 0.81 | HTR2A (0.43) | IDO1HTR2AHTR2CHTR2BATM | |
| SCHEMBL16215293 | 0.81 | HTR2A (0.40) | IDO1KMT2APAX8HTR2AHTR2C | |
| SCHEMBL20390828 | 0.79 | IDO1 (0.42) | IDO1KMT2APAX8HTR2AHTR2B | |
| SCHEMBL8125592 | 0.78 | TACR1 (0.41) | IDO1KMT2APAX8HTR2AHTR2C | |
| SCHEMBL15784567 | 0.76 | HTR2A (0.46) | IDO1KMT2APAX8HTR2AHTR2C | |
| SCHEMBL14318101 | 0.76 | HTR2A (0.46) | IDO1KMT2APAX8HTR2AHTR2C | |
| SCHEMBL16234266 | 0.76 | CES2 (0.46) | IDO1TACR1XPO1 | |
| SCHEMBL8294767 | 0.75 | HTR2A (0.62) | IDO1HTR2AHTR2CHTR2BDAO | |
| SCHEMBL20393433 | 0.74 | KMT2A (0.42) | IDO1KMT2APAX8HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135119-A1 | METHODS OF USING PROTEIN PALMITOYLATIONS INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135119-A1 | METHODS OF USING PROTEIN PALMITOYLATIONS INHIBITORS | PPT1, SPTLC2, SPTLC1 | IDO1 4042/4885KMT2A 3300/4885PAX8 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.